1295O - Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK) | D. R. Gandara (Sacramento, United States of America)

1296O - Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study

Invited Discussant 1295O and 1296O | J. Jassem (Gdańsk, Poland)

1297O - Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC) | D. R. Spigel (Nashville, United States of America)

LBA48 - ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) | D. Morgensztern (St Louis, United States of America)

LBA49 - Updated results from KEYNOTE-021 cohort G: a randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC
H. Borghaei (Philadelphia, United States of America)

Invited Discussant LBA48, LBA49 and 1297O
M. Reck (Grosshansdorf, Germany)